Abstract No. 584 PK simulation of Avatrombopag-induced increases in platelet counts with redosing in patients with thrombocytopenia and chronic liver disease

Avatrombopag (AVA) is a novel oral thrombopoietin receptor agonist recently approved to treat thrombocytopenia in patients with chronic liver disease (CLD) scheduled to undergo a procedure; it is administered orally as a 5-day treatment course. Population pharmacokinetic (PK) and PK/pharmacodynamic (PK/PD) models have been developed that characterize the relationship between AVA dosing and the induced platelet count increase. This model was used to simulate platelet count changes that could be expected with a second course of AVA.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific e-Posters Source Type: research